ArticleVeterinary clinical pathology2025
Partial Analytical Validation of microRNAs-148a and 375 for Detecting Pancreatic Injury in Healthy Dogs and Dogs With Pancreatitis.
Article in Veterinary clinical pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundmicroRNAs (miRNA) have been proposed as biomarkers for pancreatitis in dogs due to their high peak concentrations and experimental correlation with acinar cell injury. However, analytical validation and the effect of interfering substances are unknown.
objectiveThe study aimed to (i) develop and analyze the analytical validity of an assay for miRNA-148a and miRNA-375 in serum and (ii) compare miRNA-148a and miRNA-375 between healthy and pancreatitis-affected dogs.
methodsCirculating miRNAs were quantified from serum of healthy (n = 40) and pancreatitis-affected dogs (n = 40). Reference intervals were established, and serum miRNAs were compared between groups. Linearity was assessed via dilutional parallelism (observed/expected ratio, O/E). Precision was assessed via intra- and inter-assay coefficients of variation (% CV). Intralipid, bilirubin, and hemoglobin were tested as interferants.
resultsFor miRNA-148a, the RI was < 33 000 gene copies and mean O/E was 100.4%. Mean inter-assay and intra-assay % CV were 1.5% and 1.3% respectively. For miRNA-375, the RI was < 4 gene copies and mean O/E was 100.1%. Mean inter-assay and intra-assay % CV were 3.2% and 0.5% respectively. Hemolysis led to false increases in both assays (p = 0.003 - < 0.0001). miRNA-148a was reduced in dogs with pancreatitis (mean 192 gene copies) compared with healthy controls (mean 2760 gene copies; p < 0.0001), but miRNA-375 was not different between groups (p = 0.94).
conclusionsThe miRNA assays were analytically valid; however, hemolysis, a common interferant in pancreatitis cases, may impact test results. miRNA-148a was suppressed in dogs with pancreatitis. It is unclear whether this represents a cause or a consequence of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.